The global active pharmaceutical ingredient (API) market size was estimated to be US$ 225 billion in 2022 and is expected to reach US$ 407 Billion by 2032 at a CAGR of 6.1%.
Increasing investment in biopharmaceuticals, focused research and development of improved drug formulations, rising adoption of generic pharmaceuticals, prevalence of chronic disorders, and rising uptake of counterfeit drugs are the major factors influencing the growth of the global active pharmaceutical ingredients (API) market.
The manufacturers are shifting the manufacturing of active pharmaceutical ingredients in different counties around the globe which has significantly impacted the growth of market due to variance in the regulatory framework. The consumption of counterfeit drugs in the mid-income and low-income countries has increased prominently in past couple of years, which is anticipated to impact the growth of active pharmaceutical ingredients market.
However, the impact of counterfeit drugs is expected to be low owing to enforcement of strict regulations in these countries. Additionally, increasing incidences of chronic disorders such as cardiovascular disorders, cancer, and infectious diseases across the globe is expected to contribute towards the healthy growth of the global active pharmaceutical ingredients (API) market in coming years.
North America contributed the largest share to the global active pharmaceutical ingredients (API) market in 2019 and is expected to grow at a prominent rate during the forecast period owing to increasing investment in development of novel drugs, presence of leading pharmaceutical manufacturing companies, and prevalence & growth of chronic and lifestyle disorders.
Additionally, increasing investment in development of biopharmaceutical is expected to fuel the growth of North America active pharmaceutical ingredients market in coming years. The Asia Pacific is expected to be the most lucrative active pharmaceutical ingredients market due to increasing investment for expansion of pharmaceutical manufacturing and adoption of advanced healthcare technologies.
The report titled “Active Pharmaceutical Ingredients (API) Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032”, wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global active pharmaceutical ingredients (API) market.
Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market. For instance, Novartis AG reported revenues of USD 47,445 million in 2019 and the product segment analysis of the company indicates that Innovative Medicines business segment of the company dominated revenue in 2019.
The global active pharmaceutical ingredients (API) market is segmented based on type, synthesis, drug type, applications, and geography. Based on type, the global active pharmaceutical ingredients (API) market is segmented into generic active pharmaceutical ingredients, and innovative active pharmaceutical ingredients. Based on synthesis, the global active pharmaceutical ingredients (API) market is segmented into biotech, and synthetic. The biotech active pharmaceutical ingredients are sub-segmented into monoclonal antibodies, and recombinant proteins. Based on drug type, the global active pharmaceutical ingredients (API) market is segmented into prescription drugs, and over-the-counter drugs. Based on applications, the global active pharmaceutical ingredients (API) market is segmented into cardiology, oncology, CNS & neurology, orthopedic, endocrinology, pulmonology, gastroenterology, nephrology, ophthalmology, and others. Based on geography, the global active pharmaceutical ingredients (API) market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment, and would identify the segment of the company focusing on active pharmaceutical ingredients (API) products.
Further, market share of prominent companies in the global active pharmaceutical ingredients (API) market would also be estimated. For instance, Novartis AG operates through two business segments namely Innovative Medicines, and Sandoz. The active pharmaceutical ingredients (API) are delivered under Innovative Medicines business segment of the company with revenue contribution of US$ 37,714 million in 2019.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the active pharmaceutical ingredients (API) manufacturers. The global active pharmaceutical ingredients (API) market study would take into consideration the participants engaged throughout the ecosystem of the market, along with their contribution.
Product portfolio would focus on all the products under the active pharmaceutical ingredients (API) business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global active pharmaceutical ingredients (API) market.
Major players active in the global active pharmaceutical ingredients (API) market include AbbVie Inc., Albemarle Corporation, Aurobindo Pharma, Pfizer, Inc., Bayer AG., Boehringer Ingelheim International GmbH., Cipla Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Mylan N.V., Novartis AG, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Market Segmentation:
By type
By synthesis
By drug type
By applications
By geography
The active pharmaceutical ingredient (API) market is expected grow at a CAGR of 6.1% from 2023 to 2032.
The active pharmaceutical ingredient (API) market size is expected to reach US$ 407 billion by 2032.
The active pharmaceutical ingredient (API) market size was estimated to be US$ 225 billion in 2022.
Rising adoption of generic pharmaceuticals, prevalence of chronic disorders, and rising uptake of counterfeit drugs are the major factors influencing the growth of the global active pharmaceutical ingredients (API) market.
North America contributed the largest share to the global active pharmaceutical ingredients (API) market.
Some key players operating in the Active Pharmaceutical Ingredients market include AbbVie Inc., Albemarle Corporation, Aurobindo Pharma, Pfizer, Inc., Bayer AG., Boehringer Ingelheim International GmbH., Cipla Inc.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved